Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs

Incyte (INCY) PT Raised to $175 at BMO Capital; 'We Like Risk/Reward Heading into ECHO-301'

February 15, 2018 3:06 PM EST

BMO Capital raised its price target on Incyte (NASDAQ: INCY) to $175.00 (from $172.00) while maintaining an Outperform rating.

Analyst M. Ian Somaiya commented, "Despite strong fundamentals and a rich pipeline, investor focus remains singularly on the upcoming epacadostat Phase 3 melanoma data (ECHO-301), with positive... More

UPDATE: SunTrust Robinson Humphrey Reiterates Bullish View on Incyte (INCY)

February 15, 2018 2:35 PM EST

(Updated - February 15, 2018 2:50 PM EST)

(updated to expand analyst comment)

SunTrust Robinson Humphrey analyst Peter Lawson reiterated a Buy rating and $155 price target on Incyte (NASDAQ: INCY)

Lawson calls Q4 "Minor Jakafi Miss, but Focus on Epacadostat Readouts in 2018." The... More

Incyte (INCY) Q4 Revenues Beat

February 15, 2018 7:05 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of ($0.71), which may not compare to the analyst estimate of ($0.40). Revenue for the quarter came in at $444 million versus the consensus estimate of $414.16 million.

Issues Jakafi FY 2018 guidance $1.35-1.40 billion

For earnings history and earnings-related data on Incyte (INCY) click here.

... More